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Description of the evidence collection method
A literature review of the scientific articles in this guideline 
was performed in MEDLINE, Cochrane, and SciELO databases. 
The search for evidence came from real clinical scenarios 
and the following keywords (MeSH terms) grouped into 
arrangements were used: Macular Degeneration OR Age-
Related Maculopathies AND Ophthalmoscopy AND Fluores-
cein Angiography AND Tomography, Optical Coherence AND 
Antioxidants OR Vitamin E AND Photosensitizing Agents 
AND  Angiogenesis Modulating Agents AND Antibodies, 
Monoclonal AND Anti-Bacterial Agents.
Degree of recommendation and strength of evidence
A: Experimental or observational studies of higher consistency.
B: Experimental or observational studies of lesser consistency.
C: Case Reports (non-controlled studies).
D:  Opinions without critical evaluation, based on consensus, 
physiological studies, or animal models. 
Objective
To evaluate specific questions regarding the methods of 
examination, diagnosis, and treatment of age-related macular 
degeneration, resulting from evidence-based clinical practice.
Guidelines in focus
Age-related macular degeneration
Degeneração macular relacionada à idade
Conselho Brasileiro de Oftalmologia (Brazilian Council of Ophthalmology)
Projeto Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brazil
Introduction
Age-related macular degeneration (AMD), or age-related 
maculopathy, is a degenerative disease that affects the central 
portion of the retina (macula). It is the most common cause 
of visual impairment and may lead to loss of central vision 
or blindness, affecting individuals older than 50 years1 (A). In 
the early stages of age-related maculopathy, patients may be 
asymptomatic; however, in its advanced forms the disease 
may cause serious central vision dysfunction.
Although histologically the retina is a complex, multifaceted 
structure, a simpler approach is to consider it functionally 
divided into two parts: a functional entity consisting of a 
photosensitive layer of rods and cones and their neural 
connections that collect light and convert it into nervous 
electrical impulses transmitted through the optic nerve; the 
other part is the retinal pigment epithelium and its underlying 
basal lamina (Bruch’s membrane), which together maintain 
the integrity of the barrier between the choroid and the retina. 
The choroid, which is primarily a vascular tunic, is sandwiched 
between the retina and the sclera, and is the main source of 
blood supply to the outer half of the retina. 
The pathophysiology of age-related maculopathy is 
characterized by degenerative alterations involving the outer 
retina, pigment epithelium, and Bruch’s membrane2 (D). With 
advancing age, the pigment epithelium cells become less 
efficient, thus the retina can no longer receive adequate 
nutrients and waste accumulates, leading to deposits called 
amorphous drusen. Thus, the cells of the retinal pigment 
membrane slowly degenerate, resulting in central vision 
loss. This form of slowly progressive disease is called dry 
type AMD. 
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Alternatively, if the integrity of the Bruch’s membrane 
is lost, choroidal neovascular complexes grow in the 
epithelial and subretinal spaces, in a process called choroidal 
neovascularization3(D). The new blood vessels are fragile and 
incompetent, allowing for leakage and bleeding, and therefore 
leading to edema, which compromises the integrity of the 
retina, the macula, and the fovea, and progressively impairs 
visual function. The final result is a dense fibrovascular scar, 
which can involve the entire macular area4(C). This form of 
the disease is called exudative or wet type AMD, accounting 
for 90% of cases of severe vision loss in the elderly. 
AMD is a multifactorial disease of unknown etiology. Several 
risk factors are known, among which age is the strongest5,6(A).
Ocular risk factors include the presence of soft drusen, macular 
pigmentary alterations, and choroidal neovascularization in 
the other eye. Systemic risk factors include hypertension, 
smoking, and positive family history7,8(A)9(D).
The most common AMD symptoms are central vision 
blurring, metamorphopsia (image distortion), and reduced 
vision, which may lead to central scotoma and significant 
vision loss. Ophthalmoscopic fundus examination shows dry 
type irregular chorioretinal atrophy and exudative macular 
edema, often associated with retinal hemorrhages and lipid 
exudates around the macula.
1. What examination is necessary for the initial 
diagnosis of age-related macular degeneration?
The fundus examination with dilated pupils (fundoscopy, 
retinal mapping, or biomicroscopic fundus) is the recom-
mended initial approach for AMD diagnosis. A common 
condition related to aging and of unknown cause, the disease 
has varied symptoms and may be asymptomatic in the early 
stages. Only one eye may have reduced visual acuity, whereas 
the other may maintain good vision for many years. When 
both eyes are affected, the loss of central vision is perceived 
early. It is recommended for all patients aged 55 years or older 
to determine the risk of developing the more severe forms of 
the disease10(A).
Recommendation
Fundus examination with dilated pupils is recommended for 
the initial diagnosis of AMD.
2. For the diagnosis and follow-up of exudative 
age-related macular degeneration, should only 
fluorescein angiography be performed, or optical 
coherence tomography as well?
Fluorescein angiography is an examination that consists of 
the intravenous administration of a contrast, fluorescein 
(a non-toxic and highly fluorescent molecule). It allows for 
the study of the characteristics of blood flow in the retina 
and choroid vessels, recording details of the pigment 
epithelium and retinal circulation, as well as providing 
evaluation of its functional integrity. Optical coherence 
tomography (OCT) is a diagnostic procedure that uses light 
to obtain and create an image of the retina and optic disc. 
Using a technique known as low-coherence interferometry 
for optical measurements, OCT’s principle of operation is 
similar to that of ultrasound, using light instead of sound. 
The scanner light is focused on the retina, and the computer 
analyzes the amount of reflected light, thereby creating an 
image of the analyzed tissue, previously only possible in 
histological studies. 
When exudative AMD is suspected, it is recommended 
to perform at least fluorescein angiography and, whenever 
possible, OCT. The sensitivity of each of these tests to 
detect macular edema of different etiologies is high, and the 
correlation between them is good (sensitivity of 96.1% and 
98.7% for OCT and fluorescein angiography, respectively)11(B). 
However, some discrepancy is found between the methods, as 
subtle edemas are identified only by fluorescein angiography, 
with no corresponding alteration detected in retinal thickness 
by OCT (3.86% of cases of macular disease are observed only 
by fluorescein angiography)11(B).
Recommendation
Both fluorescein angiography and OCT have high sensitivity, 
with good correlation to detect macular diseases. However, 
there is a small chance that, when used alone, they may not 
detect subtle cases of macular disease.
3. Should all patients older than 65 years,  
in the presence of drusen and pigmentary 
alterations in the macular region be treated 
with minerals and antioxidants to prevent 
maculopathy progression to the exudative  
forms and prevent loss > 15 letters in the ETDRS 
eye chart?
It has been suggested that the disease progression may be 
decreased in individuals who eat a diet rich in antioxidant 
vitamins (carotenoids, vitamins C and E) and minerals (zinc 
and selenium). Oxidative damage to the retina may be related 
to the pathogenesis of AMD, because the retina, due to its 
high oxygen concentration and intense light exposure, is 
susceptible to damage by oxidative stress12(D). Patients with 
age-related maculopathy of the non-exudative type have 
different probabilities of progressing to the exudative forms 
or of having maculopathy-related visual acuity loss. 
A multicenter randomized clinical trial designed to 
evaluate the effect of high doses of zinc, selected antioxidant 
vitamins (among which, vitamins E, C, and beta carotene 
administered at 5 to 15 times the recommended daily dose), 
and zinc supplements in the development of advanced forms 
of age-related maculopathy in elderly patients (55 to 80 years 
old), showed that patients in category 2 (extensive small 
drusen, pigmentary alterations, non-extensive intermediate 
drusen) showed a probability of only 1.3% of progressing to 
advanced forms of disease after five years of follow-up. 
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 Patients in category 3 (extensive intermediate drusen, large 
drusen or non-central geographic atrophy), had an estimated 
probability of 18% (ranging from 6% in patients with extensive 
intermediate drusen, up to 27% in those with large drusen 
and/or extrafoveal geographic atrophy). Patients in category 4 
(patients with age-related maculopathy advanced in one eye or 
loss of visual acuity in one eye related with non-exudative type 
maculopathy) had a probability of around 43% of progression 
in five years. Therefore, categorizing patients in groups is 
important to determine the risk of maculopathy progression 
and of visual acuity deterioration10,13(A).
In patients classified in categories 3 and 4, the use of 
vitamins and minerals (500 mg vitamin C, 400 IU vitamin E, 
15 mg beta-carotene, 80 mg zinc, and 2.0 mg copper) prevented 
loss of vision (15 letters in the ETDRS eye chart), demonstrating 
RRR = 21% with 95% CI: 3% to 38%, and NNT = 17 (95% CI: 9-17). 
There was also a reduction in the risk of progression to more 
advanced forms of age-related maculopathy (RRR = 29% with 
95% CI: 11% to 46% and NNT = 12 (95% CI: 8-33)10(A).
Recommendation
Only patients classified as belonging to category 3 (extensive 
intermediate drusen, large drusen or non-central geographic 
atrophy), especially those who have at least three factors 
in the simplified severity scale (presence of large drusen or 
pigmentary alterations or extensive intermediate drusen in 
both eyes) and category 4 (patients with advanced age-related 
maculopathy in one eye or loss of visual acuity in one eye 
related to non-exudative maculopathy) should be treated with 
antioxidants and zinc. Patients in the lower categories should 
be followed and treated if they progress to higher severity 
categories.
4. What are the side effects of antioxidant 
and zinc use in the treatment of age-related 
maculopathy and what are the  
contraindications?
The main potential side effects are kidney stones associated 
with vitamin C, fatigue, muscle weakness, decreased thyroid 
function, increased risk of hemorrhagic stroke associated with 
vitamin E, increased risk of developing lung cancer in smokers, 
and yellowing of the skin, associated with beta carotene, 
anemia, decreased HDL, gastric discomfort caused by zinc; in 
patients that use antioxidants, the main complaint observed 
was yellowing of skin, when compared to the control group 
(8.3% versus 6%, respectively)10(A).There was a significant 
increase in hospital admissions due to genitourinary tract 
diseases in individuals who received zinc supplementation 
(11.1% versus 7.6%, p = 0.0003)14(A).
Recommendation
When treating patients, it is the physician’s responsibility 
to explain the nature of supplementation and the potential 
side effects caused by long-term use and, especially, the 
contraindication to the use of beta-carotene in smokers, and 
vitamin E in diabetic patients with vasculopathies15(A).
5. What is the benefit of using intravitreal 
ranibizumab in the treatment of neovascular 
age-related macular degeneration?
Although the physiopathological mechanism is not fully 
established, evidence suggests that the vascular endothelial 
growth factor, VEGF-A, is an important mediator involved 
in the angiogenesis and vascular permeability alterations in 
neovascular AMD (wet or exudative type)16,17(C). Numerous 
anti-VEGF molecules, with ranibizumab among them, have 
been developed in order to limit the deleterious effects of 
choroidal neovascular formation associated with AMD, mainly 
by reducing the permeability of new abnormal vessels, as 
well as reducing the rate of neovascular progression (growth), 
which often lead to loss of central vision in the affected 
eye. Ranibizumab, an antibody fragment of recombinant 
humanized monoclonal anti-vascular endothelial growth 
factor for intravitreal use, has been extensively studied in 
several clinical trials, which evaluated its safety and benefit, 
using different dosages and treatment regimens for that 
purpose18-21(A).
In another clinical trial, including several centers with a 
24-months duration, patients with neovascular AMD and 
minimally classic lesions or some component of hidden 
choroidal neovascularization (CNV) without angiographic 
evidence of classic CNV were randomized to treatment with 
intravitreal ranibizumab, at monthly doses of 0.3 mg or 0.5 mg, 
compared to monthly sham injections. After 12 months 
of treatment, patients treated monthly with intravitreal 
ranibizumab (0.3 mg and 0.5 mg) showed less loss of visual 
acuity compared to those who received sham injections (94.5% 
of patients receiving 0.3 mg of ranibizumab and 94.6% of those 
receiving 0.5 mg had lost up to 15 letters, at the evaluation 
through the ETDRS eye chart of basal visual acuity, when 
compared to 62.2% of those who received the sham injection 
[p < 0.001])18(A). 
The beneficial results regarding visual acuity at 12 months 
were maintained with continued treatment at 24 months - 
92% of patients that received 0.3 mg of ranibizumab, and 90% 
of those receiving 0.5 mg had lost up to 15 letters (ETDRS 
eye chart) of basal visual acuity, when compared to 52.9% 
of those who received the sham injection (p < 0.001)18(A).
Regarding ocular adverse events in patients submitted to 
monthly treatment with intravitreal ranibizumab during 
the analysis period of 24 months, uveitis was reported 
in 1.3%, presumed endophthalmitis (negative culture in 
4 of 5 cases) in 1.0%, retinal tear in 0.4%, and vitreous 
hemorrhage in 0.4%; vitreous hemorrhage was observed in 
0.8% of patients who underwent sham intravitreal injection, 
and rhegmatogenous retinal detachment in 0.4%18(A). In a 
multicenter clinical trial with a 24-month duration, patients 
with neovascular AMD and predominantly classic lesions 
were randomized to treatment with monthly intravitreal 
injections of ranibizumab at doses of 0.3 mg or 0.5 mg (both 
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associated with sham verteporfin photodynamic therapy) 
or treatment with photodynamic therapy with active 
verteporfin (associated with sham intravitreal injections). 
After a period of 12  months, patients treated with 
monthly ranibizumab intravitreal injections (0.3 mg and 
0.5 mg) presented less loss of visual acuity compared to 
those undergoing photodynamic therapy with verteporfin. 
94.3% of patients receiving 0.3 mg of ranibizumab and 96.4% 
of those receiving 0.5 mg of ranibizumab showed loss of 
up to 15 letters (ETDRS eye chart) of basal visual acuity 
compared to 64.3% of those undergoing photodynamic 
therapy with verteporfin (p < 0.001)19,20(A). Regarding ocular 
adverse events in the same period, the following were 
identified in patients undergoing intravitreal ranibizumab: 
uveitis in 0.4%, rhegmatogenous retinal detachment in 0.4%, 
and vitreous hemorrhage in 0.4%. Rhegmatogenous retinal 
detachment was observed in 0.7% of patients undergoing 
photodynamic therapy with verteporfin19(A). In both clinical 
trials19,20(A), all participants completed the 25-item National 
Eye Institute visual function questionnaire (NEI VFQ-25) at 
baseline and after 24 months.
In the clinical trial including patients with neovascular 
AMD lesions and minimally classic lesions or some 
component of occult CNV with no angiographic evidence of 
classic CNV, those treated with doses of 0.3 mg and 0.5 mg of 
intravitreal ranibizumab had a mean score of improvement 
in the visual function questionnaire of +5.2 (95% CI: +3.5 to 
+6.9) and +5.6 (95% CI: +3.9 to +7.4) points, respectively, at 
the end of the first year of treatment. In contrast, patients 
submitted to sham intravitreal injections had a mean score 
of -2.8 (95% CI: -4.6 to -1.1) points in the same period, and 
this difference was significant, favoring the use of intravitreal 
ranibizumab22(A). In a clinical trial including patients with 
neovascular AMD and predominantly classic lesions, treated 
with doses of 0.3 mg and 0.5 mg of intravitreal ranibizumab 
associated with photodynamic therapy with verteporfin, there 
was improvement in the mean score of the visual function 
questionnaire of +5.9 (95% CI: +3.6 to +8.3) and +8.1 (95% CI: 
+5.3 to +10.8) points, respectively, at the end of the first year 
of treatment. 
In contrast, patients treated with verteporfin photodynamic 
therapy had a mean score of +2.2 (95% CI: -0.3 to +4.7) points 
in  the same period, and this difference was significant, 
favoring the use of intravitreal ranibizumab23(A). At each visit 
up to 24 months, patients treated with intravitreal ranibizumab 
showed greater chances of improvement in most subscales, 
including pre-specified ones (near activities, distance activities, 
and vision-specific dependency). 
Recommendation
Based on the results obtained in multicenter randomized 
controlled trials, the angiogenic drug modulation (or anti-
angiogenic therapy or vascular endothelial growth antifactor 
therapy) with ranibizumab, via intravitreal appli cation for a 
period of two years in patients with AMD showed significant 
improvement in visual acuity, with low rates of adverse 
events.
6. When should treatment of neovascular 
age-related macular degeneration with 
intravitreal ranibizumab be started?
In order to obtain favorable results concerning visual acuity, 
efforts should be made in order to shorten the time from 
diagnostic confirmation to the start the angiogenic drug 
modulation with intravitreal ranibizumab, since neovascular 
choroid lesions (subfoveal) can progress rapidly, at an average 
rate of approximately 10 micrometers per day24,25(C).
In multicenter clinical trial lasting 24 months, patients 
with neovascular AMD lesions, minimally classic or with 
some component of occult CNV, and with no angiographic 
evidence of classic CNV, were randomized to treatment 
with intravitreal ranibizumab at monthly doses of 0.3 mg or 
0.5 mg, compared to monthly sham injections. After 12 and 
24 months, approximately 1/4 of the patients treated with 
0.3 mg ranibizumab and 1/3 of the patients treated with 0.5 mg 
showed gains of 15 or more letters (ETDRS eye chart) of visual 
acuity compared with 5% or less of patients undergoing sham 
injections (p < 0.001)18(A). The administration of ranibizumab 
(0.3 mg and 0.5 mg) resulted in visual acuity improvement 
within the first seven days after use, while visual acuity in 
patients submitted to sham injections showed decline over 
the follow-up period18(A). 
Another multicenter randomized clinical trial observed, 
soon after the first month of follow-up, poor visual acuity 
in patients submitted to sham injections, when compared 
to  those receiving ranibizumab doses of 0.3  mg and 
0.5 mg26(A).
Recommendation
Angiogenic drug modulation with intravitreal ranibizumab 
for the treatment of neovascular AMD must be initiated as 
soon as possible, preferably within a period of one month 
after diagnosis confirmation, respecting obvious limitations 
inherent to the treatment process, such as obtaining the 
relatively high-cost medication. 
7. Is the use of topical antibiotics before 
each treatment session (intravitreal injection) 
mandatory?
Recent advances in the treatment of retinal diseases have 
made intravitreal injections an increasingly common route 
of drug administration. However, this procedure is not 
risk-free, and endophthalmitis is one of the most serious 
complications, with reported incidences ranging from 0.02% 
to 1.9% per injection27,28(C). Other complications described 
include retinal detachment and acute cataracts29(A). Since 
endophtalmitis is a devastating complication, ocular surface 
preparation prior to the procedure remains controversial, but 
it has been acknowledged in a prospective study that the use 
of topical 5% povidone-iodine preoperatively reduces the risk 
of endophthalmitis after intraocular procedure30(B).
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A clinical trial reported the incidence of endophthalmitis 
after intravitreal drug administration using a standardized 
protocol that required topical povidone-iodine and sterile 
blepharostat, but did not require the use of gloves or sterile 
drapes or use of topical antibiotics (before, on the same 
day, or after intravitreal injection procedure). Topical 
antibiotics were used on the day of administration in 9.4% 
of 3,838 intravitreal injections, for several days after the 
administration in 21.2%, and on the day of administration, 
as well as after, in 36.2%. In the remaining 1,276 intravitreal 
injections (33.3%), topical antibiotics were not used. Three 
cases of endophthalmitis were observed, confirmed by culture 
after intravitreal ranibizumab injection (0.09%), and all cases 
had used antibiotics for several days after the intravitreal 
procedure31(A).
Recommendation
The results suggest that a low rate of endophthalmitis can be 
attained by applying a protocol that includes the use of topical 
povidone-iodine, sterile blepharostat, and topical anesthesia, 
without the need of topical antibiotics, gloves, and sterile 
drapes. 
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